ArticleScientific reports2025
Exploring the therapeutic potential of Kirkia tenuifolia Engl. stem bark extract and its bioactive compounds through experimental and computational approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kirkia tenuifolia Engl. (family Kirkiaceae) is traditionally used to treat cholera, alleviate thirst, and serves as an important water source and livestock feed in arid regions. However, to date, no scientific study has been conducted on its chemical composition and pharmacological properties. Therefore, the present study aimed to isolate and identify the chemical constituents from the stem bark of Kirkia tenuifolia Engl and evaluate their pharmacological activities. Silica gel chromatographic separation of the methanol extract afforded nine compounds (1-9), identified herein for the first time from this species. Among them, lupeol (2) exhibited notable antibacterial activity with an MIC of 0.625 mg/mL against E. coli, S. typhi, and P. aeruginosa. Dimethylfraxetin (5), urolithin M5 (6) and urolithin M5 (7) showed antibacterial activity with an MIC of 0.625 mg/mL against E. coli and P. aeruginosa. Compounds 2, 5, 6, and 7 demonstrated potent antioxidant activities in the DPPH assay, with IC₅₀ values ranging from 2.58 to 9.00 µg/mL. The methanol extract showed significant cytotoxicity against MCF-7 breast cancer cells (34.96% viability at 200 µg/mL) and antiviral activity against influenza A (H1N1) (CC₅₀ = 39.8, IC₅₀ = 4.2 µg/mL, SI = 9.1). Molecular docking revealed that compound 7 exhibited higher binding affinities with S. aureus pyruvate kinase (-7.2 kcal/mol) and L. monocytogenes receptor (-7.4 kcal/mol) compared to ciprofloxacin (-5.6 and - 6.2 kcal/mol, respectively). Lupeol (2) showed stronger binding to Prdx5 (-6.1 kcal/mol) than ascorbic acid (-5.2), while compounds 2, 5, 6, and 7 bound more strongly to human myeloperoxidase (-7.4 to -8.6) than ascorbic acid (-4.8). These findings support the therapeutic potential of Kirkia tenuifolia Engl, but further studies are needed to confirm its effects against diverse pathogens and cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.